Microbial stereospecific reduction of 3-quinuclidinone with newly isolated Nocardia sp. and Rhodococcus erythropolis

[1]  Y. Makino,et al.  Efficient synthesis of optically pure alcohols by asymmetric hydrogen-transfer biocatalysis: application of engineered enzymes in a 2-propanol–water medium , 2012, Applied Microbiology and Biotechnology.

[2]  S. Sentellas,et al.  Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[ , 2009, Journal of medicinal chemistry.

[3]  Nobuhito Kurono,et al.  Practical Asymmetric Hydrogenation of 3-Quinuclidinone Catalyzed by the XylSkewphos/PICA−Ruthenium(II) Complex , 2009 .

[4]  Kazuhiro Watanabe,et al.  Microbial production of (S)-1-phenyl-1,3-propanediol by stereospecific reduction of 3-hydroxy-1-phenylpropane-1-one , 2009 .

[5]  M. Kataoka,et al.  Stereoselective synthesis of (R)-3-quinuclidinol through asymmetric reduction of 3-quinuclidinone with 3-quinuclidinone reductase of Rhodotorula rubra , 2009, Applied Microbiology and Biotechnology.

[6]  M. Nei,et al.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.

[7]  R. Odžak,et al.  Synthesis of new N-quaternary-3-benzamidoquinuclidinium salts. , 2006, Molecules.

[8]  M. Takeuchi,et al.  Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists. , 2005, Journal of medicinal chemistry.

[9]  B. Zhong,et al.  Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018). , 2005, Bioorganic & medicinal chemistry letters.

[10]  Y. Nie,et al.  Highly Enantioselective Conversion of Racemic 1-Phenyl-1,2-ethanediol by Stereoinversion Involving a Novel Cofactor-Dependent Oxidoreduction System of Candida parapsilosis CCTCC M203011 , 2004 .

[11]  F. Nomoto,et al.  A practical chemoenzymatic process to access (R)-quinuclidin-3-ol on scale , 2003 .

[12]  F. Nomoto,et al.  There's No Industrial Biocatalyst Like Hydrolase: Development of Scalable Enantioselective Processes Using Hydrolytic Enzymes1 , 2003 .

[13]  S. Tomić,et al.  Stereoselective Hydrolysis of Quaternary Quinuclidinium Benzoates Catalyzed by Butyrylcholinesterase , 2003 .

[14]  Y. Ni,et al.  Asymmetric reduction of aryl ketones with a new isolate Rhodotorula sp. AS2.2241 , 2002 .

[15]  H. Bjørsvik,et al.  A new modified montanari oxidation process by means of chlorine dissolved in the reaction solvent as oxidant and TEMPO as catalyst: Oxidation of 3-S-quinuclidinol to 3-quinuclidinone , 2002 .

[16]  W. Roth,et al.  Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  V. Alabaster.  Discovery & development of selective M 3 antagonists for clinical use , 1997 .

[18]  M. Chartrain,et al.  Asymmetric Bioreduction of Cyclohexylphenyl Ketone to Its Corresponding Alcohol (+) Cyclohexylphenyl Alcohol by the Yeast Candida Magnoliae MY 1785 , 1997 .

[19]  C. Caccia,et al.  Serotoninergic 5-HT3 and 5-HT4 receptor activities of dihydrobenzofuran carboxylic acid derivatives , 1996 .

[20]  M. Chartrain,et al.  Asymmetric bioreduction of a β-tetralone to its corresponding (S)-alcohol by the yeast Trichosporon capitatum MY 1890 , 1996 .

[21]  J. Ferkany,et al.  Affinity and selectivity of the optical isomers of 3-quinuclidinyl benzilate and related muscarinic antagonists. , 1988, Journal of medicinal chemistry.

[22]  M. Rehavi,et al.  Enzymatic resolution and cholinergic properties of (+/-)3-quinuclidinol derivatives. , 1977, Life sciences.